The whistleblower claims brought by a former sales representative for Abbott Laboratories alleging that the company illegally marketed its drug TriCor for off-label uses have survived a motion to dismiss in federal court.
The case falls in line with the Third Circuit's shift toward a more relaxed pleading standard for off-label marketing claims under Federal Rule of Civil Procedure 9(b).
